서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 31 of 31

Issue DateTitle / Author(s) / CitationFileAltmetrics
2007-05
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2008-03
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
DOI
2011-08
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
DOI
2016-08
Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial
DOI
2017-10
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
DOI
2017-12
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
DOI
2018-09
Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
DOI
2018-10
BGJ398, a pan-FGFR inhibitor, overcomes paclitaxel resistance in urothelial carcinoma with FGFR1 overexpression
DOI
2019-01
Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients
DOI
2019-02
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
DOI
2019-02
Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial
view fileDOI
2019-11
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
DOI
2020-07
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
DOI
2021-01
Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
DOI
2021-09
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
DOI
2022-05
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
DOI
2022-12
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
DOI
2023-02
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
DOI
2023-03
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
DOI
2023-11
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
DOI
2024-02
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
DOI
2024-02
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
DOI
2024-02
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
view fileDOI
2024-05
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
DOI
2024-05
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Kitagawa, Yuko; Matsuda, Satoru; Gotoda, Takuji; Kato, Ken; Wijnhoven, Bas; Lordick, Florian; Bhandari, Pradeep; Kawakubo, Hirofumi; Kodera, Yasuhiro; Terashima, Masanori; Muro, Kei; Takeuchi, Hiroya; Mansfield, Paul F.; Kurokawa, Yukinori; So, Jimmy; Monig, Stefan Paul; Shitara, Kohei; Rha, Sun Young; Janjigian, Yelena; Takahari, Daisuke; Chau, Ian; Sharma, Prateek; Ji, Jiafu; de Manzoni, Giovanni; Nilsson, Magnus; Kassab, Paulo; Hofstetter, Wayne L.; Smyth, Elizabeth Catherine; Lorenzen, Sylvie; Doki, Yuichiro; Law, Simon; Oh, Do-Youn; Ho, Khek Yu; Koike, Tomoyuki; Shen, Lin; van Hillegersberg, Richard; Kawakami, Hisato; Xu, Rui-Hua; Wainberg, Zev; Yahagi, Naohisa; Lee, Yeong Yeh; Singh, Rajvinder; Ryu, Min-Hee; Ishihara, Ryu; Xiao, Zili; Kusano, Chika; Grabsch, Heike Irmgard; Hara, Hiroki; Mukaisho, Ken-ichi; Makino, Tomoki; Kanda, Mitsuro; Booka, Eisuke; Suzuki, Sho; Hatta, Waku; Kato, Motohiko; Maekawa, Akira; Kawazoe, Akihito; Yamamoto, Shun; Nakayama, Izuma; Narita, Yukiya; Yang, Han-Kwang; Yoshida, Masahiro; Sano, Takeshi

Gastric Cancer, Vol.27 No.3, pp.401-425

DOI
2024-06
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINYPanTumor01): an international, phase 2 study
DOI
2024-08
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2024-11
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
DOI
2025-02
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
DOI
2025-02
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer
DOI
2025-05
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
DOI
1